When treating cancer, time is critical. That’s what makes the use of AI in oncology so pivotal. Today, AI is helping researchers identify potential clinical trial participants earlier, before critical windows close. The goal: more patients gaining access to investigational therapies and accelerated drug discovery. Discover how AI is already reshaping cancer research: https://lnkd.in/eytQhGVd #AIinHealthcare #OncologyResearch #ClinicalTrials #InnovationInMedicine #Biopharma #HealthTech #PatientAccess
關於我們
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
- 網站
-
https://www.pfizer.com/?source=Linkedin
外部輝瑞連結
- 產業
- 製藥製造
- 公司規模
- 10,001+ 名員工
- 總部
- New YorkNew York
- 類型
- 上市公司
- 專長
- To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe和effective and affordable medicines and health care services to the people who need them.
地點
輝瑞員工
動態消息
-
Scott and Natalie, medicinal chemists at Pfizer, and their lab work to create and isolate compounds to be tested as potential drug candidates. During this process, compounds must be closely monitored and extensively tested to confirm their purity and ensure they match the scientists’ intended design. Watch our latest #WhatsInMyLab to learn more about this process and some of the tools involved. #Science #Innovation
What’s In My Lab
-
As colorectal cancer rates rise in young adults, advances in science are offering new hope for patients. This story explores how updated screening guidelines, advances in precision medicine, along with strides in research and education, are helping to reshape what’s possible. Read more: https://lnkd.in/gAi7QYq4 #ColorectalCancerAwarenessMonth #ColorectalCancer #CancerResearch #PrecisionMedicine
-
-
Pfizer is proud to champion this initiative led by Amyloidosis Research Consortium. Pre-competitive initiatives like ASPIRE allow organizations to pool expertise, accelerate research, and address challenges that are too complex for any one company to solve alone. By focusing on shared goals—such as expediting suspicion and recognition of ATTR-CM—we hope to create impact at scale, ultimately benefiting patients and public health with the single goal to address health disparities and accelerate progress in diagnosis and care. Learn more here: Brighter Together: https://lnkd.in/epgMZ7YM
ASPIRE (Amyloidosis Stakeholder Partnerships for Improved Research and Equity) now has a home on LinkedIn. This community connects patient advocates, researchers, clinicians, and industry partners working to improve how amyloidosis is diagnosed and treated. Follow along for research updates, new publications, and news from across the amyloidosis landscape. This page will serve as a central resource for: • Updates on ASPIRE initiatives and research collaborations • Examples of partnership and shared impact in rare disease • Opportunities to engage with ongoing programs and discussions Follow ASPIRE to stay informed as collaboration continues to advance more equitable outcomes for people affected by amyloidosis. Learn more: arci.org/aspire
-
-
Today we announced positive topline results from a Phase 2 study of our potential first-in-class IL4/13 and TSLP trispecific antibody in #AtopicDermatitis. Learn more about these encouraging results, and how they support Pfizer’s plan to advance a broad development program for Type 2 (Th2) inflammatory conditions, here: https://lnkd.in/eABvkvVk
Pfizer has announced positive topline results from a Phase 2 study of our potential first-in-class IL4/13 and TSLP trispecific antibody in #atopicdermatitis. These results support advancement to Phase 3 development, with a pivotal study in atopic dermatitis planned to start this year. Read the press release here: https://lnkd.in/eJzzeQJw These data underscore the continued momentum of our pipeline and reflect Pfizer’s refreshed R&D strategy, focused on delivering breakthrough medicines across four core therapeutic areas, including Inflammation & Immunology. By targeting multiple pathways in a single molecule, this innovative biologic, discovered and developed in-house at Pfizer, has the potential to transform treatment paradigms in inflammatory conditions. We plan to advance a broad clinical development program across atopic dermatitis and other Th2-mediated inflammatory diseases, including asthma and COPD.
-
Metastatic Breast Cancer (MBC), a more advanced and invasive form of breast cancer, affects approximately 170,000 women in the US alone and remains a leading cause of cancer-related deaths globally. Though recent improvements in screening are already helping achieve better health outcomes, there is still a critical need for new therapies to help further reduce the impact of the disease, which currently remains incurable. Driven by this goal, our scientists are working every day, applying their expertise and cutting-edge technology to design and develop innovative therapeutic candidates. Learn more about a discovery that will hopefully bring them one step closer to a potential advancement in first-line care for certain forms of MBC: https://lnkd.in/d-D-hje7 #Oncology #BreastCancer #CancerResearch #BehindTheScience
Behind the Science | Metastatic Breast Cancer
-
Here at Pfizer, we pursue scientific breakthroughs that change patients’ lives, but none of our innovations would reach the patients in need without our manufacturing powerhouse — Pfizer Global Supply or PGS. Our high-tech and robust pharmaceutical manufacturing infrastructure combined with the hard work of our dedicated PGS colleagues makes it possible for Pfizer to deliver medicines and vaccines to patients where and when they need them. Watch Pfizer’s US supply network in action. https://lnkd.in/gjVT3eKV
-
-
A potential hidden driver of cachexia is a stress signal called GDF-15. Elevated levels of GDF-15 are linked to more severe symptoms of cachexia, including appetite loss, fatigue, and muscle wasting. In our latest explainer, we describe what GDF-15 is and how new research aims to understand the underlying biology of this condition. Click here to learn about cachexia, who it affects, and some of our preliminary findings: https://lnkd.in/gfq8wj2u
What is GDF-15?
-
2025 was a strong year for Pfizer and we continued to deliver breakthroughs that change patients' lives. We are looking ahead to 2026 with focus, confidence, and an unwavering commitment to patients.
We just shared our Q4 and full-year results, and I couldn't be more proud of what we delivered. I'm even more optimistic about what's ahead. In 2026, we're pursuing up to twenty pivotal studies across our portfolio. And with Metsera, we're moving fast in obesity, including today's encouraging new Phase 2 data for our ultra-long-acting GLP-1. This is Pfizer at our best. We can't wait to share more progress soon.
-
Hanna’s interest in science began at an early age, influenced by her father’s career. Now working at Pfizer as a scientist herself, she brings purpose to her work, driven by the belief that determination and scientific rigor can make a meaningful difference for patients. That mindset is central to the work we do and the people who make it possible. #Science #Innovation
Hanna's Interest in Science